BrandMemo | manage and share brands you love  Pharmamedix su Facebook  Pharmamedix su Twitter
 Home | News | About us | Comitato scientifico | Iscriviti | Utenti | Etica | Contenuti | Guida | Faq | Stage | Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Quetiapina

Seroquel, Quentiax e altri

Bibliografia - Quali fonti bibliografiche per Quetiapina?


         
  1. Agenzia Italiana del Farmaco – AIFA, Nota informativa, 2015, Agosto.

  2. Arvanitis L.A., Miller B.G., Biol. Psychiatriy, 1997, 42, 233.

  3. Ballard C. et al., Cochrane Database of Systemic Reviews, 2006, Issue 1.

  4. Ballard C. et al., BMJ, 2005, 330 (7496), 874.

  5. Bauer M. et al., J. Clin. Psychiatry, 2009, 70 (4), 540.

  6. Borison R.L. et al., J. Clin. Psychopharmacol., 1996, 16 (2), 158.

  7. Bowden C.L. et al., J. Clin. Psychiatry, 2005, 66 (1), 111.

  8. Brown E.S. et al., Bipolar Disorder, 2002, 4 (6), 406.

  9. Calabrese J.R et al., Am. J. Psychiatry, 2005, 162 (7), 1351.

  10. Cerullo M.A, Strakowski S.M., Subst. Abuse Treat. Prev. Policy, 2007, 2, 29.

  11. Cheung G., Stapelberg J., N.Z. Med. J., 2011, 124 (1336), 39.

  12. Correll C. et al., JAMA, 2009, 302 (16), 1765.

  13. Cutler A.J. et al., J. Clin. Psychiatry, 2009, 70 (4), 526.

  14. El-Khalili N. et al., Int. J. Neuropsychopharmacol., 2010, 13 (7), 917.

  15. FDA Public Health Advisory, 2010, http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.

  16. Feret M.B., Caley C.F., Ann. Pharmacother., 2000, 34 (4), 483.

  17. Finding R.L. et al., J. Child. Adolesc. Psychopharmacol., 2012, 22 (5), 327.

  18. Fleischhacker W.W., Link C.G., 34th Annu. Meet. Am. Coll. Neuropsychopharmacol., 1995, dicembre 11-15, San Juan.

  19. Fraunfelder F.W., Am. J. Ophthalmol., 2004, 138 (5), 870.

  20. Gao K. et al., J. Clin. Psychopharmacol., 2008, 28 (2): 203.

  21. Gill S.S. et al., BMJ, 2005, 330 (7489),445.

  22. Goldstein J.M., 38th Annu. Meet. New Clin. Drug Eval. Unit Program, 1998, giugno 10-13, Boca Raton. 1998.

  23. Goldstein J.M., 38th Annu. Meet. New Clin. Drug Eval. Unit Program, 1998, giugno 10-13, Boca Raton. 1998a.

  24. Grimm S.W. et al., Schizophr. Res., 1997, 24, 198.

  25. Harmon T.J. et al., J. Toxicol. Clin. Toxicol., 1998, 36 (6), 599.

  26. Herrmann N. et al., Am. J. Psychiatry, 2004, 161 (6), 1113.

  27. Huybrechts K.F. et al., BMJ, 2012, Feb 23;344:e977. doi: 10.1136/bmj.e977.

  28. Jin H. et al., J. Clin. Psychiatry., 2012, doi:10.4088/JCP.12m08001.

  29. Jones P.B. et al., Arch. Gen. Psychiatry, 2006, 63 (10), 1079.

  30. Juncos J. et al., 37th Annu. Meet. Am. Coll. Neuropsychopharmacol., 1998, dicembre 14-18, Las Croabas, PR.

  31. Juncos J.L. et al., Mov. Disord., 2004, 19 (1), 29.

  32. Kales H.C. et al., Am. J. Psychiatry, 2012, 169 (1), 71.

  33. Kapur S., Seeman P., Am. J. Psychiatry, 2001, 158 (3), 360.

  34. Kapur S. et al., Arch. Gen. Psychiatry, 2000, 57 (6), 553.

  35. Lee P.E. et al., BMJ, 2004, 329 (7457), 75.

  36. Leucht S. et al., Lancet, 2009, 373, 31.

  37. Lieberman J.A. et al., NEJM, 2005, 353 (12), 1209.

  38. Liperoti R. et al., Arch. Intern. Med., 2005, 165 (22), 2677.

  39. Maneeton N. et al., BMC Psychiatry, 2012, 12 (1), 160.

  40. Mannu P. et al., Rivista di psichiatria, 2006, 41, 5.

  41. McIntyre R.S. et al., Eur. Neuropsychopharmacol., 2005, 15 (5), 573.

  42. McKean A., Monasterio E., CNS Drug, 2012, 26 (5), 383.

  43. MHRA, Medicines and Healthcare Regulatory Agence, Antipsychotic drugs, 2012 www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antipsychoticdrugs/index.htm#l4

  44. Metha S. et al., J. Clin. Psychiatry, 2010, 71 (6), 689.

  45. Mullen J. et al., 37th Annu. Meet. Am. Coll. Neuropsychopharmacol., 1998, dicembre 13-18, San Juan.

  46. NICE - National Institute for Health and clinical excellence, Depression. The treatment and management of depression in adults, 2010.

  47. Noss M.B. et al., Drug of Today, 1999, 35 (3), 211.

  48. Nudelman E. et al., J. Clin. Psychiatry, 1998, 59 (8), 433.

  49. Peacock L. et al., Psychopharmacol., 1996, 124, 188.

  50. Penaskovic K.M. et al., Prim. care Companion. J. Clin. Psychiatry, 2010, 12 (5), doi:pii: PCC.09l00939. 10.4088/PCC.09l00939yel.

  51. Peuskens J., Link C.G., Acta Psychiatric. Scand., 1997, 96, 265.

  52. Peuskens J. et al., Int. J. Psychiatr. Clin. Pract., 2007, 11 (1), 61.

  53. Pollak P.T., Zbuk K., Clin. Pharmacol. Ther., 2000, 68 (1), 92.

  54. Sachs G. et al., Bipolar Disord., 2004, 6 (3), 213.

  55. San L. et al., Psychiatry Res., 2012, 200 (2-3), 693.

  56. Schneider L. et al., 152nd Annu. Meet. Am. Psychiatric. Assoc., 1999, maggio 15-20, Washington, DC.

  57. Schneider L.S. et al., Am. J. Geriatr. Psychiatry, 2006, 14 (3), 191.

  58. Shotbolt P et al., Ther. Adv. Neurol., Disord., 2010, 3 (6), 339.

  59. Small J.G. et al., Arch. Gen. Psychiatry, 1997, 54 (6), 549.

  60. Suppes T. et al., Ann. J. Psychiatry, 2009, 166 (4), 476.

  61. Suttajit S. et al., Drug Des. Devel. Ther., 2014, 8, 827.

  62. Thyrum P.T. et al., Psychopharmacol. Bull., 1996, 32, 524A.

  63. Torun F. et al., Turk. Psikiyatri derg., 2011, 22 (3), 195.

  64. Tsai A.C., J. Clin. Psychopharmacol., 2011, 31 (2), 235.

  65. Vieta E., Goikolea J.M., Bipolar Disorders, 2005, 7 (Suppl. 4), 21.

  66. Vieta E. et al., Curr. Med. Res. Opin., 2005, 21 (6), 923.

  67. Weisler R. et al., CNS Spectr., 2009, 14 (6), 299.

  68. Wong Y.W. et al., J. Clin. Psychopharmacol., 2001, 21 (1), 89.

  69. Wong Y.W. et al., Psycopharmacol. Bull., 1997, 33, 605.

  70. Yang F.W., Liang C.S., Gen. Hosp. Psychiatry, 2011, 33 (3), 302.

  71. Yatham L.N. et al., J. Clin. Psychopharmacol., 2004, 24 (6), 599.